149 related articles for article (PubMed ID: 27273830)
1. PBX3 is a putative biomarker of aggressive prostate cancer.
Ramberg H; Grytli HH; Nygård S; Wang W; Ögren O; Zhao S; Løvf M; Katz B; Skotheim RI; Bjartell A; Eri LM; Berge V; Svindland A; Taskén KA
Int J Cancer; 2016 Oct; 139(8):1810-20. PubMed ID: 27273830
[TBL] [Abstract][Full Text] [Related]
2. Regulation of PBX3 expression by androgen and Let-7d in prostate cancer.
Ramberg H; Alshbib A; Berge V; Svindland A; Taskén KA
Mol Cancer; 2011 May; 10():50. PubMed ID: 21548940
[TBL] [Abstract][Full Text] [Related]
3. Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer.
Gerke T; Beltran H; Wang X; Lee GM; Sboner A; Karnes RJ; Klein EA; Davicioni E; Yousefi K; Ross AE; Börnigen D; Huttenhower C; Mucci LA; Trock BJ; Sweeney CJ
Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):584-590. PubMed ID: 30420441
[TBL] [Abstract][Full Text] [Related]
4. Deregulation of a Hox protein regulatory network spanning prostate cancer initiation and progression.
Chen JL; Li J; Kiriluk KJ; Rosen AM; Paner GP; Antic T; Lussier YA; Vander Griend DJ
Clin Cancer Res; 2012 Aug; 18(16):4291-302. PubMed ID: 22723371
[TBL] [Abstract][Full Text] [Related]
5. PBX3 promotes migration and invasion of colorectal cancer cells via activation of MAPK/ERK signaling pathway.
Han HB; Gu J; Ji DB; Li ZW; Zhang Y; Zhao W; Wang LM; Zhang ZQ
World J Gastroenterol; 2014 Dec; 20(48):18260-70. PubMed ID: 25561793
[TBL] [Abstract][Full Text] [Related]
6. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
[TBL] [Abstract][Full Text] [Related]
7. Novel alternative PBX3 isoforms in leukemia cells with distinct interaction specificities.
Milech N; Kees UR; Watt PM
Genes Chromosomes Cancer; 2001 Nov; 32(3):275-80. PubMed ID: 11579467
[TBL] [Abstract][Full Text] [Related]
8. PBX3 Is Part of an EMT Regulatory Network and Indicates Poor Outcome in Colorectal Cancer.
Lamprecht S; Kaller M; Schmidt EM; Blaj C; Schiergens TS; Engel J; Jung A; Hermeking H; Grünewald TGP; Kirchner T; Horst D
Clin Cancer Res; 2018 Apr; 24(8):1974-1986. PubMed ID: 29391352
[No Abstract] [Full Text] [Related]
9. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
[TBL] [Abstract][Full Text] [Related]
10. Silencing Pre-B-cell leukemia homeobox 3 decreases the proliferation of human glioma cells in vitro and in vivo.
Xu X; Cai N; Bao Z; You Y; Ji J; Liu N
J Neurooncol; 2017 Dec; 135(3):453-463. PubMed ID: 28856521
[TBL] [Abstract][Full Text] [Related]
11. Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma.
Claudio PP; Zamparelli A; Garcia FU; Claudio L; Ammirati G; Farina A; Bovicelli A; Russo G; Giordano GG; McGinnis DE; Giordano A; Cardi G
Clin Cancer Res; 2002 Jun; 8(6):1808-15. PubMed ID: 12060621
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
[TBL] [Abstract][Full Text] [Related]
13. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
[TBL] [Abstract][Full Text] [Related]
14. Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy.
Chen WY; Hua KT; Lee WJ; Lin YW; Liu YN; Chen CL; Wen YC; Chien MH
Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27455254
[TBL] [Abstract][Full Text] [Related]
15. Retinoic acid regulates the expression of PBX1, PBX2, and PBX3 in P19 cells both transcriptionally and post-translationally.
Qin P; Haberbusch JM; Soprano KJ; Soprano DR
J Cell Biochem; 2004 May; 92(1):147-63. PubMed ID: 15095411
[TBL] [Abstract][Full Text] [Related]
16. The transcription factor PBX3 promotes tumor cell growth through transcriptional suppression of the tumor suppressor p53.
Li WF; Herkilini A; Tang Y; Huang P; Song GB; Miyagishi M; Kasim V; Wu SR
Acta Pharmacol Sin; 2021 Nov; 42(11):1888-1899. PubMed ID: 33526870
[TBL] [Abstract][Full Text] [Related]
17. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
[TBL] [Abstract][Full Text] [Related]
18. Hox gene products modulate the DNA binding activity of Pbx1 and Pbx2.
van Dijk MA; Peltenburg LT; Murre C
Mech Dev; 1995 Jul; 52(1):99-108. PubMed ID: 7577680
[TBL] [Abstract][Full Text] [Related]
19. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
20. Prostate extracellular vesicles in patient plasma as a liquid biopsy platform for prostate cancer using nanoscale flow cytometry.
Biggs CN; Siddiqui KM; Al-Zahrani AA; Pardhan S; Brett SI; Guo QQ; Yang J; Wolf P; Power NE; Durfee PN; MacMillan CD; Townson JL; Brinker JC; Fleshner NE; Izawa JI; Chambers AF; Chin JL; Leong HS
Oncotarget; 2016 Feb; 7(8):8839-49. PubMed ID: 26814433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
